AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$BLRX

BioLineRx Ltd.

Price · $BLRXvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $BLRX in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $BLRX in the last 30 days.

Top stories · $BLRXMore →
APR 1·Stock TitanLow

BioLineRx (BLRX) director details extensive stock option grants

BioLineRx Ltd. director Sandra Panem filed an initial ownership report, Form 3, detailing a significant number of employee stock options to purchase ordinary shares. These options include various blocks with different exercise prices and expiration dates ranging from 2026 to 2034. Footnotes indicate that older grants through 2024 are fully vested, while a substantial portion of a more recent October 2024 grant will vest quarterly, conditional on continued service.

MAR 31·Stock Titan

BioLineRx (BLRX) director discloses 2,055,000 option-linked shares

BioLineRx Ltd. director Cohen Gal Avraham has filed an initial ownership report detailing employee stock options for 2,055,000 ordinary shares. These options have an exercise price of $0.052 per share and expire on August 14, 2034, granted under the company’s 2003 Amended and Restated Share Incentive Plan. As of the grant date, 856,200 options were vested, with the remainder vesting in seven equal quarterly installments, subject to continued service.

FEB 23·TipRanks

BioLineRx Wins Arbitration Ruling in Motixafortide Licensing Dispute

BioLineRx secured a full arbitration victory in a dispute with Biokine Therapeutics over alleged unpaid amounts related to a motixafortide licensing agreement. The arbitrator denied Biokine's $7.2 million claim and awarded BioLineRx legal expenses, resolving a financial and legal uncertainty for the biopharmaceutical company. This decision strengthens BioLineRx's financial position and clarifies its obligations regarding the motixafortide program.

News on $BLRX

All news →